

Monday, November 23, 2009

[Feedback](#) | [Helpdesk](#) | [Sign up](#) | [Login](#)

To print: [Click here](#) or Select **File** and then **Print** from your browser's menu

► **Clinical Trials**

Ecron Acunova opens new office in Russia to tap clinical trials opportunities

Saturday, November 21, 2009 08:00 IST

Our Bureau, Bangalore

Ecron Acunova, a full-service clinical research organization (CRO), with offices across Europe, India and the US, has strengthened its Eastern European presence further by opening a new office in Moscow. Galyna Andriyko will lead the development of the Russian office operations.

"This is another key step for Ecron Acunova in creating a unique platform for clients to fully benefit from the strengths of global reach with local expertise. Russia has substantial unexplored capabilities. With its 141 million population and well recognized experience in clinical trials, Russia allows high recruitment rates, low drop-out rates and high quality data, to be obtained by dedicated medical professionals," Dr Antal K Hajos, managing director & CEO, Ecron Acunova, Europe, said.

Ecron Acunova has 23 years of clinical expertise. Across Europe alone, Ecron Acunova covers 14 countries. In CEE Ecron Acunova has own offices since 2004 in the Czech Republic (Prague), Poland (Warsaw) and Ukraine (Kyiv). Through the new office in Russia, Ecron Acunova expands its current success in delivering client focused services. With its strong presence and local expertise, the company manages the most challenging time, costs and quality demands of its clients in the key clinical trial markets of the region.

"With Andriyko's expertise, we look forward to strengthening clinical trials in this region. Andriyko has successfully set up operations in Ukraine, delivering high quality results at competitive costs with personalised services. The clinical team will be headed by Dr Vlad Linievych, a physician, who has over 13 years of experience in industry. Ecron Acunova has been active in Russia for several years via collaborations and enjoys sound contacts to clinical trial sites," added Dr Hajos.